FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

NOVEMBER 2026

An Emerging Global Leader in a New Generation of Anti-Infectives

Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) is an Australian clinical stage biotech company engaged in the development and commercialisation of **a new class of Synthetic Anti-infectives designed to address the urgent global health problem of antimicrobial resistant (AMR) superbugs.**

Recce's lead candidate, RECCE® 327 (R327), is a patented, **broad-spectrum synthetic anti-infective being developed in multiple formulations, including intravenous and topical.** It is designed to treat serious bacterial infections, including those caused by drug-resistant **Gram-positive** and **Gram-negative** pathogens.

- **Products address the global healthcare crisis of antibiotic resistance**: working faster than traditional antibiotics and against multidrug resistant bacteria
- **Patient dosing well underway for Phase 3 clinical trials in Indonesia and Australia** of lead asset RECCE® 327 Gel for the treatment of Diabetic Foot Infections
- **Independent data monitoring committee currently reviewing unblinded data**; with potential commercialisation in 2027
- **Signed an exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals** for R327G in AU and NZ
- **Non-binding term sheet signed with a leading Middle Eastern pharmaceutical company** for a proposed 10-year exclusive, multi-country licensing agreement
- **Multiple clinical indications and formulations addressing unmet medical needs**
- **Agreements with US Defense Burn Research Program and US Army Medical Research Institute of Infectious Diseases** further support Recce's product potential

RECCE® 327 Topical Gel



INDONESIA	MENA	GLOBAL
>20 million	**>84 million**	**>589 million**
adults in Indonesia with diabetes	adults in MENA region with diabetes	adults globally with diabetes

SNAP SHOT

Ticker	ASX:RCE, FSE:R9Q
Date listed	January 2016, March 2021
52 week range	AUD $0.2650 – A$0.7300
Market Cap	AUD $111.63m (priced at $0.3550)
Shares on issue	305.84m
3 month avg. vol	256.36K (per trading day)
Sector	Pharmaceuticals, Biotechnology & Life Sciences

BOARD AND MANAGEMENT

Dr John Prendergast	Executive Chairman
James Graham	Managing Director & Chief Executive Officer
Michele Dilizia	Executive Director & Chief Scientific Officer
Dr Justin Ward	Executive Director & Principal Quality Chemist
Dr Alan W Dunton	Chief Medical Advisor & Non-Executive Director
Arthur Kollaras	Head of Manufacturing
Justin Reynolds	CFO (Outsourced – Pitcher Partners Sydney)
Maggie Niewidok	Company Secretary (Outsourced – Kardos Scanlan)

PATENT PORTFOLIO

Recce's patent portfolio contains over 40 patents and patent applications in the world's major markets.

FILED	PATENT FAMILY 1	PATENT FAMILY 2	PATENT FAMILY 3	PATENT FAMILY 4
Australia	✓	✓	✓	✓
USA	✓	✓	✓	Pending
Europe	✓	✓	✓	Pending
Germany	✓	✓	✓	
Spain	✓	✓	✓	
France	✓	✓	✓	
UK	✓	✓	✓	
Italy	✓	✓	✓	
Sweden	✓	✓	✓	
Japan	✓	✓	✓	✓
China	✓	✓	✓	✓
HK	Pending	Pending	✓	✓
Canada				✓
Israel				✓
Brazil				✓
Vietnam				✓

Family 1 (expiry 2028) (France and USA - 2029)
Protecting Recce's unique and highly economical manufacturing process.

Family 2 (expiry 2037)
Protecting Recce's drug delivery opportunities.

Family 3 (expiry 2037)
Antiviral agent and method for treatment of viral infection.

Family 4 (expiry 2041)
Process for Preparation of Biologically Active Copolymer

Other Patent Cooperation Treaty - pending/allowed

**The Advanced Finding is a binding, underwritten guarantee provided by the Australian Government, which affirms the Company's R&D activities are of national interest and extends the 43.5% R&D rebate from locally, to cover those undertaken by the Company anywhere in the world for a period of three years. This finding does not constitute a grant, or an upfront payment of the amount awarded*

RECCE® 327 Mechanism of Action




Stage 1
R327 targets and irreversibly binds to essential bacterial proteins

Stage 2
R327 disrupts bacterial metabolism and depletes ATP at the cell surface

Stage 3
R327 kills bacteria rapidly without inducing cell lysis

Stage 4
R327 is rapidly and irreversibly bactericidal

RECCE® Multiple Anti-Infective Applications



- Approval received from the Indonesian Drug and Food Regulation Authority, Badan POM, to initiate its Registrational Phase 3 clinical trial in Indonesia
- ABSSSI includes postoperative infection, wound infections and diabetic foot infections
- Completed pilot civil Phase II Burn Wound Infections Study; US$2M grant for Department of Defense pre-clinical pipeline in progress
- Cooperative Research and Development Agreement signed with US Army Medical Research Institute of Infectious Diseases, to test R327 against biothreat pathogens in established *in vitro* models.

Efficacy - RECCE® 327

- Achieved a 93% positive clinical response in diabetic foot infection (DFI) patients during Phase II trials, with **no serious adverse events reported**
- Multiple SAS Category A patient cases in Australia have shown **rapid clinical improvement with RECCE® 327 Topical Gel**, including the avoidance of surgical intervention in severe infections
- In SAS Category A use, R327 demonstrated visible reductions in swelling, redness, and infection progression within 24–72 hours of a single application
- **Maintains potency across both Gram-positive and Gram-negative bacteria, including their drug-resistant variants**
- Time-kill studies show RECCE® 327 acts faster than conventional antibiotics, rapidly depleting bacterial ATP and causing irreversible bacterial death
- **Demonstrated 99.9% *in vitro* efficacy against the full suite of ESKAPEE pathogens**

Safety - RECCE® 327

- **R327 has been shown to be safe and well tolerated across multiple Phase I and II clinical trials and/or SAS Category A patient cases – as either intravenous or topical gel**
- Phase I trials demonstrated intravenous **safety profile even at high doses up to 6,000 mg** delivered over a one-hour infusion
- No clinically significant changes were observed in laboratory tests, EKGs, telemetry, or vital signs, supporting systemic safety
- R327 displayed a clear therapeutic window across multiple dosing schedules and concentrations
- **Topical application has shown to be non-irritating and well tolerated, even in infected, open wound sites**
- **Multiple R327 studies of mutagenicity (cancer) are clear**

recce.com.au

Sydney – Head Office
Level 15, 1 Farrer Place
Governor Macquarie Tower
Sydney NSW 2000
Australia

Macquarie Park – Production
Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre
Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations
Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

Recce Pharmaceuticals Ltd makes no warranties or representations regarding the accuracy or completeness of the information contained in this investor fact sheet. Certain statements made may contain forward looking statements, which involve known and unknown risk, uncertainties and other factors, which may cause the actual results or performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements.